Mazdutide (IBI362) is a long-acting dual GLP-1/glucagon receptor agonist developed for chronic weight management and type 2 diabetes. Phase 2 and 3 clinical trials have demonstrated substantial weight loss (6-14% reduction over 24-48 weeks) with mostly mild gastrointestinal side effects.
Appetite Regulation
Peptides mimic satiety hormones, reducing hunger signals from the brain.
Quickstart Highlights
- Dosage: 2.5-5mg
- Frequency: Weekly
- Administration: Subcutaneous
- Cycle length: Ongoing
Dosing Plan
| Weeks | Dose | Units |
|---|---|---|
| Weeks 1–2 | 1.5mg once weekly | 45 units (0.45mL) |
| Weeks 3–4 | 2.5mg once weekly | 75 units (0.75mL) |
| Weeks 5–8 | 3.5mg once weekly | 105 units (1.05mL) |
| Weeks 9+ (Maintenance) | 5mg once weekly | Use higher concentration or multiple injections |
How to mix
Add 3.0mL bacteriostatic water per 10mg vial → ~3.33mg/mL concentration
- Draw 3.0mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall.
- Gently swirl until dissolved.
- Label with date and refrigerate at 2–8°C.
Syringe Math Reference
- 10mg vial with 3mL BAC water = 3.33 mg/mL
- 1 unit = 0.01mL ≈ 33.3mcg
- 1.5mg = 45 units
- 2.5mg = 75 units
- 3.5mg = 105 units
What you'll need
Mazdutide Vials (10mg)
- 4 weeks 1 vial
- 8 weeks 2 vials
- 12 weeks 3 vials
Insulin Syringes (U-100)
- 4 weeks 4 syringes
- 12 weeks 12 syringes
Bacteriostatic Water (10mL)
- 12 weeks 1 bottle
Alcohol Swabs
- 12 weeks 1 × 100-count box
How This Works
Mazdutide is a dual agonist that activates both GLP-1 and glucagon receptors. GLP-1 receptor activation promotes satiety, slows gastric emptying, and improves glucose control. Glucagon receptor activation enhances energy expenditure and promotes hepatic fat oxidation. The combination may provide synergistic effects for weight loss and metabolic improvement.
Mechanism of Action
How Mazdutide Works in Your Body
Peptide Administered
Enters bloodstream and travels to target receptors
Brain Signaling
Binds to GLP-1 receptors in the hypothalamus
Appetite Reduced
Signals satiety — you feel full sooner
Fat Metabolism
Body shifts to burning stored fat for energy
Benefits & Side Effects
Potential Benefits
- Significant weight loss (6-14% in trials)
- Enhanced energy expenditure
- Improved glucose control
- Hepatic fat reduction
- Appetite suppression
Potential Side Effects
- Nausea (common)
- Vomiting
- Diarrhea
- Decreased appetite
- Injection site reactions
How to store it
- Lyophilized: Freeze at −20°C (−4°F).
- Reconstituted: Refrigerate at 2–8°C.
- Avoid freeze–thaw cycles.
Good to know
- Dual GLP-1/glucagon receptor agonist.
- Phase 2/3 trials show 6-14% weight loss.
- Gradual titration essential to minimize GI side effects.
- Similar to retatrutide but dual (not triple) agonist.
- Currently in clinical development.
Community Insights
Summarised from 3 sourcesMazdutide (IBI362) is a long-acting dual GLP-1/glucagon receptor agonist developed for chronic weight management and type 2 diabetes. Phase 2 and 3 clinical trials have demonstrated substantial weight loss (6-14% reduction over 24-48 weeks) with mostly mild gastrointestinal side effects. Gradual tit
Common Dosages Reported
- 2.5-5mg Weekly
- Standard protocol dosing
Side Effects Mentioned
- Generally mild, individual variation expected
- See full guide for detailed safety info
Stacking Suggestions
- Consult research and healthcare provider before stacking
What people are saying
Results vary based on individual response
Consistent dosing and timing important
Reviews & Discussion
Real experiences shared by the community — not medical advice.
Mazdutide weight loss efficacy compared to Retatrutide and Tirzepatide
A user shared a positive experience with Mazdutide, noting that it was more effective for weight loss than Retatrutide. They reported losing 14 lbs in one month and described it as being much more potent than Tirzepatide.
Positive mental effects and appetite suppression with Mazdutide
A member reported a very positive initial experience with Mazdutide at a 3mg starting dose, noting feelings of euphoria and energy similar to their experience with Tirzepatide. They highlighted a significant reduction in hunger and food noise without experiencing common side effects like fatigue, nausea, or heartburn. The user found it compared favorably to a 10mg dose of Tirzepatide despite being on a low starting dose.
Pharmacological Comparison and Ratio Analysis
A user analyzed the pharmacological profile of Mazdutide, noting that it is a dual agonist of GLP-1 and glucagon receptors. They highlighted that Mazdutide features a significantly higher ratio of GLP-1 receptor agonism compared to glucagon receptor activity, distinguishing it from other dual agonists like Pemvidutide.
Clinical Trial Discussion
A user discussed the clinical trial results for Mazdutide, noting a promising 18.6% weight loss over a 48-week period. They expressed optimism about the increasing number of pharmacological options and research developments in the weight loss peptide space.
No discussion yet — be the first.
No notes yet — be the first.